Table of Contents
- 1 Is Asensus a good stock to buy?
- 2 What happened to Asensus surgical?
- 3 Is Asensus surgical?
- 4 Does TransEnterix have a future?
- 5 Where is Asensus surgical located?
- 6 Is TRXC FDA approved?
- 7 What is a lap procedure?
- 8 Does TransEnterix have FDA approval?
- 9 Should you invest in ASXC surgical technology stock?
- 10 Should you buy asensus (ASXC)?
- 11 What does senhance’s expansion mean for asensus surgical?
Is Asensus a good stock to buy?
Zacks’ proprietary data indicates that Asensus Surgical, Inc. is currently rated as a Zacks Rank 4 and we are expecting a below average return from the ASXC shares relative to the market in the next few months.
What happened to Asensus surgical?
Asensus Surgical sells a robot-assisted surgery system called Senhance Surgical. After the market closed on Wednesday, the company reported third-quarter results that impressed investors.
What does Asensus Surgical do?
Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.
Is Asensus surgical?
Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU).
Does TransEnterix have a future?
TransEnterix has projected its cash runway to last until the end of 2022. There are also many regulatory catalysts anticipated in the first half of 2020 that can further push up share prices. TransEnterix is expecting the FDA’s clearance for use of the Senhance system in general surgery indication.
Is Senhance FDA approved?
Indication expansion allows Senhance’s use in high-value, complex reconstructive surgeries. Asensus Surgical (formerly TransEnterix) has received an additional FDA clearance for the Senhance Surgical System that has expanded its indication to general surgery in the U.S.
Where is Asensus surgical located?
Overview Suggest Edit
Type | Public |
---|---|
Founded | 2006 |
HQ | Durham, NC, US |
Website | asensus.com |
Is TRXC FDA approved?
Asensus Surgical announces FDA clearance for Senhance Surgical System. Asensus Surgical, formerly TransEnterix, Inc. (NYSEMKT:TRXC) has announced that the company received an additional FDA clearance for the Senhance Surgical System sending TransEnterix shares ~28.1\% higher in the pre-market.
Will TransEnterix survive?
TransEnterix (NYSEAMERICAN:TRXC) now has plenty of cash to survive well into 2024, which will allow the laparoscopy robotics company to eventually produce revenue.
What is a lap procedure?
Laparoscopy is a type of surgical procedure that allows a surgeon to access the inside of the abdomen (tummy) and pelvis without having to make large incisions in the skin. This procedure is also known as keyhole surgery or minimally invasive surgery.
Does TransEnterix have FDA approval?
TransEnterix Surgical Inc. today announced that the U.S. Food and Drug Administration has granted it 510(k) clearance to add the Intelligent Surgical Unit, a machine vision enhancement, to its Senhance robot-assisted surgical system.
Will TRXC survive?
Should you invest in ASXC surgical technology stock?
Technological innovation in the surgical space is still at a nascent stage. According to one report, the global digital surgery technologies market is expected to reach $5.11 billion by 2030 from $252.5 million in 2019 , growing at a CAGR of 32.1\% from 2020 to 2030. Hence, there is a lot to gain for a company like ASXC stock.
Should you buy asensus (ASXC)?
For ASXC stock, this figure stands at 4.6\%, pretty low, all things considered. Hence, when deciding to invest in Asensus, you have to decide whether you are interested in the company’s long-term story. Unlike several meme stocks, this one has a story that has legs to run.
Why should you hold asasensus surgical (Asas) in your portfolio?
Asensus Surgical has a viable product in the Senhance laparoscopic system, a revolutionary tool that aims to improve the elective surgery procedure process. Since the company’s platform involves machine learning and AI, investors have reason to be bullish regarding its future. The company realizes this as well.
What does senhance’s expansion mean for asensus surgical?
“The indication expansion allows Senhance to be used in many high-value, complex reconstructive surgeries such as those used to treat reflux and obesity,” Asensus Surgical president and CEO Anthony Fernando said on the occasion.